NCT06941077View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

June 3, 2025

Study Completion Date

June 3, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

INCB057643

Tablet

Trial Locations (1)

85283

Celerion, Inc, Tempe

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY